Posted by Michael Wonder on 22 Jan 2018
Biogen ‘optimistic’ for NHS access to Spinraza
22 January 2018 - Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales.
According to the firm, NICE has formally invited the group to submit Spinraza (nusinersen), which it notes is the first and only disease-modifying treatment for the condition, for assessment via the Single Technology Appraisal route.
Spinal muscular atrophy is an autosomal recessive neuromuscular, serious, debilitating, and life-threatening rare disease, and is the leading genetic cause of death in infants.
